방법 비교

	연구 프로토콜에서의 위험-이익 평가	취약 인구 집단 연구
분야	연구윤리	연구윤리
계열	Process / pipeline	Process / pipeline
기원 연도	1979	1979
창시자	U.S. Department of Health and Human Services; International research ethics community	U.S. Department of Health and Human Services; World Health Organization; International research ethics community
유형	Framework	Guideline
원전	The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979). The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.	U.S. Department of Health and Human Services. (2018). Protection of Human Subjects. Code of Federal Regulations Title 45, Part 46, Subparts B, C, D.
별칭	risk-benefit analysis, risk-benefit calculation, risk-benefit justification, harm-benefit ratio	vulnerable subjects, special populations, vulnerable groups, additional protections
관련	5	5
요약	A risk-benefit assessment is a systematic evaluation of the potential harms and benefits of a proposed research study, documented in ethics committee applications. The Belmont Report (1979) established the principle of beneficence—maximizing benefits while minimizing harm—as a cornerstone of research ethics. Regulatory frameworks (45 CFR 46.111 in the U.S., equivalent in other jurisdictions) require ethics committees to determine that risks are reasonable in relation to anticipated benefits before approving research. This assessment is not a simple calculation (risks + benefits) but a qualitative judgment incorporating probability, magnitude, and distribution of harms and benefits.	Vulnerable populations are groups with limited capacity to protect themselves due to age, cognitive ability, institutional dependency, or social circumstances. Regulatory frameworks in the U.S. (45 CFR 46 Subparts B, C, D) and internationally identify specific vulnerable populations—children, prisoners, pregnant women, cognitively impaired individuals—and mandate additional ethical protections beyond standard informed consent. These protections include obtaining informed consent from surrogate decision-makers (parents, guardians), additional assurances of minimal risk, and enhanced monitoring for safety. Research ethics committees apply heightened scrutiny to studies involving vulnerable populations and may deny approval if special protections are inadequate.